After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
FDA sets June date for latest review of Merck’s last-ditch antibioticThe FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new Share XFDA sets June date for latest review of Merck’s last-ditch antibiotichttps://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodThe EMA’s main advisory committee has backed approval of Novo Nordisk’s oral GLP-1 agonist Rybelsus, a key pipeline Share XNovo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodhttps://pharmaphorum.com/news/novo-nordisk-nears-eu-okay-for-oral-semaglutide-after-chmp-nod/
Alnylam gets CHMP backing for second gene-silencing drug GivlaariAlnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share XAlnylam gets CHMP backing for second gene-silencing drug Givlaarihttps://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKThe top EU court has endorsed an earlier decision by the UK financial regulator to fine GlaxoSmithKline in Share XECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKhttps://pharmaphorum.com/news/ecj-backs-uk-regulators-pay-for-delay-fine-levied-on-gsk/
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
Child with rare disease takes NICE to court over access to life-changing therapyNICE’s decision-making process will come under legal scrutiny in court this week, after a child and her family Share XChild with rare disease takes NICE to court over access to life-changing therapyhttps://pharmaphorum.com/news/child-with-rare-disease-takes-nice-to-court-over-access-to-life-changing-therapy/
Lilly, Boehringer bag FDA okay for diabetes triple Trijardy XREli Lilly and Boehringer Ingelheim’s longstanding alliance in diabetes has delivered another new product, this time a three-drug Share XLilly, Boehringer bag FDA okay for diabetes triple Trijardy XRhttps://pharmaphorum.com/news/lilly-boehringer-bag-fda-okay-for-diabetes-triple-trijardy-xr/
